FI115460B - Menetelmä terapeuttisesti käyttökelpoisen 5-(2-(4-(1,2-bentsisotiatsol-3-yyli)-1-piperatsinyyli)etyyli)-6-kloori-1,3-dihydro-2H-indol-2-onihydrokloridin monohydraatin valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisen 5-(2-(4-(1,2-bentsisotiatsol-3-yyli)-1-piperatsinyyli)etyyli)-6-kloori-1,3-dihydro-2H-indol-2-onihydrokloridin monohydraatin valmistamiseksi Download PDF

Info

Publication number
FI115460B
FI115460B FI933804A FI933804A FI115460B FI 115460 B FI115460 B FI 115460B FI 933804 A FI933804 A FI 933804A FI 933804 A FI933804 A FI 933804A FI 115460 B FI115460 B FI 115460B
Authority
FI
Finland
Prior art keywords
monohydrate
benzisothiazol
piperazinyl
dihydro
chloro
Prior art date
Application number
FI933804A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI933804A0 (fi
FI933804A (fi
Inventor
Frank R Busch
Dennis M Godek
Douglas J M Allen
Sabeto A Diroma
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI933804A0 publication Critical patent/FI933804A0/fi
Publication of FI933804A publication Critical patent/FI933804A/fi
Application granted granted Critical
Publication of FI115460B publication Critical patent/FI115460B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI933804A 1992-09-01 1993-08-31 Menetelmä terapeuttisesti käyttökelpoisen 5-(2-(4-(1,2-bentsisotiatsol-3-yyli)-1-piperatsinyyli)etyyli)-6-kloori-1,3-dihydro-2H-indol-2-onihydrokloridin monohydraatin valmistamiseksi FI115460B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93920492 1992-09-01
US07/939,204 US5312925A (en) 1992-09-01 1992-09-01 Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride

Publications (3)

Publication Number Publication Date
FI933804A0 FI933804A0 (fi) 1993-08-31
FI933804A FI933804A (fi) 1994-03-02
FI115460B true FI115460B (fi) 2005-05-13

Family

ID=25472737

Family Applications (1)

Application Number Title Priority Date Filing Date
FI933804A FI115460B (fi) 1992-09-01 1993-08-31 Menetelmä terapeuttisesti käyttökelpoisen 5-(2-(4-(1,2-bentsisotiatsol-3-yyli)-1-piperatsinyyli)etyyli)-6-kloori-1,3-dihydro-2H-indol-2-onihydrokloridin monohydraatin valmistamiseksi

Country Status (21)

Country Link
US (1) US5312925A (pt)
EP (1) EP0586191A1 (pt)
JP (1) JP2742372B2 (pt)
KR (2) KR100278321B1 (pt)
CN (1) CN1033641C (pt)
AU (1) AU657231B2 (pt)
BR (1) BR9303014A (pt)
CA (1) CA2105114C (pt)
CZ (1) CZ285984B6 (pt)
DE (1) DE9312903U1 (pt)
EG (1) EG20251A (pt)
FI (1) FI115460B (pt)
HU (1) HU221725B1 (pt)
IL (1) IL106777A (pt)
MX (1) MX9305277A (pt)
NO (1) NO300270B1 (pt)
NZ (1) NZ248543A (pt)
PL (2) PL174396B1 (pt)
RU (1) RU2081116C1 (pt)
TW (1) TW422845B (pt)
ZA (1) ZA936394B (pt)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
ES2083319B1 (es) * 1993-09-20 1997-01-16 Pfizer Monohidrato de clorhidrato de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil)-6-cloro-1,3-dihidro-2h-indol-2-ona.
DK0790236T3 (da) * 1996-02-13 2004-02-23 Pfizer Prolægemidler af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2H-indol-2-on
WO1997042190A1 (en) * 1996-05-07 1997-11-13 Pfizer Inc. Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US7030142B1 (en) * 1999-04-06 2006-04-18 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using ziprasidone metabolites
US7175855B1 (en) * 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
EA003907B1 (ru) * 1999-05-27 2003-10-30 Пфайзер Продактс Инк. Композиция зипразидона в виде суспензии
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
PE20011061A1 (es) 2000-02-01 2001-11-20 Procter & Gamble Cristalizacion selectiva del acido 3-piridil-1-hidroxi-etiliden-1,1-bisfosfonico sodio como el hemipentahidrato o el monohidrato
PE20011065A1 (es) 2000-02-01 2001-11-21 Procter & Gamble Proceso para fabricar bisfosfonatos geminales
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
ATE503845T1 (de) * 2001-12-10 2011-04-15 Novartis Pharma Gmbh Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
EP1505967B1 (en) * 2002-05-17 2016-07-13 Duke University Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
PT1556378E (pt) * 2002-10-24 2008-02-21 Pfizer Prod Inc Derivados acil de 5-2-(4-(1,2 benzisotiazol-3-il)-1- piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona com actividade neuroléptica
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
AU2003300814A1 (en) 2002-12-04 2004-06-23 Dr. Reddy's Laboratories Inc. Polymorphic forms of ziprasidone and its hydrochloride
CN1255105C (zh) * 2002-12-17 2006-05-10 上海医药工业研究院 齐拉西酮及其盐的水溶性包合物及其制备方法
WO2004089948A1 (en) * 2003-04-11 2004-10-21 Hetero Drugs Limited Novel crystalline forms of ziprasidone hydrochloride
SI2316456T1 (sl) * 2003-04-29 2017-10-30 Orexigen Therapeutics, Inc. Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion
RU2005135454A (ru) * 2003-05-16 2006-06-27 Пфайзер Продактс Инк. (Us) Терапевтические комбинации атипичных нейролептиков с модуляторами гамк и/или противосудорожными препаратами
EP1546146A1 (en) * 2003-06-03 2005-06-29 Teva Pharmaceutical Industries Limited POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION
US20050049295A1 (en) * 2003-06-12 2005-03-03 Dr. Reddy's Laboratories Limited Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
US7667037B2 (en) * 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
DK1689721T3 (da) * 2003-11-26 2010-09-20 Pfizer Prod Inc Aminopyrazolderivater som GSK-3-ihibitorer
AU2003285600A1 (en) * 2003-11-28 2005-06-24 Siddiqui Mohammed Jaweed Mukarram Process for the preparing ziprasidone monohydrochloride hydrate
CA2550485A1 (en) * 2003-12-18 2005-07-07 Teva Pharmaceutical Industries Ltd. Polymorphic form b2 of ziprasidone base
CA2552126A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Ziprasidone formulations
US7429580B2 (en) * 2004-01-13 2008-09-30 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
WO2005085240A2 (en) * 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Process for the preparation of ziprasidone
WO2005100348A1 (en) * 2004-04-15 2005-10-27 Lupin Limited Amorphous ziprasidone hydrochloride
US20050233010A1 (en) * 2004-04-19 2005-10-20 Satow Philip M Lithium combinations, and uses related thereto
RU2006139930A (ru) * 2004-05-03 2008-06-10 Дюк Юниверсити (Сша/Сша) (Us) Составы для содействия снижению веса
WO2005107719A2 (en) * 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
ITMI20040944A1 (it) * 2004-05-11 2004-08-11 Dinamite Dipharma S P A In For Polimorfo di ziprasidone cloridrato e procedimento per la sua preparazione
CA2467538C (en) * 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
WO2005123086A2 (en) * 2004-06-11 2005-12-29 Dr. Reddy's Laboratories Ltd. Ziprasidone dosage form
CA2471219A1 (en) * 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
ES2310366T3 (es) * 2004-08-24 2009-01-01 Janssen Pharmaceutica Nv Nuevos derivados de heteroaril sulfonamida benzo-condensada utiles como agentes anticonvulsivos.
US9044503B2 (en) * 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
CA2487003C (en) * 2004-11-05 2012-03-13 Apotex Pharmachem Inc. Process for the preparation of ziprasidone (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one)
WO2006086779A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Amorphous ziprasidone mesylate
CA2500667C (en) * 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
US20060270685A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Anhydrous ziprasidone mesylate and a process for its preparation
EP1858891A2 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
PE20061318A1 (es) * 2005-04-22 2006-12-28 Wyeth Corp Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos
AU2006249577A1 (en) * 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
HU230479B1 (hu) * 2006-05-02 2016-07-28 Richter Gedeon Nyrt. Eljárás 5-{2-[4-(1,2-benzizotiazol-3-il)-1-piperazinil]-etil}-6-klór-1,3-dihidro-2H-indol-2-on (Ziprasidon) előállítására
AU2007253814A1 (en) * 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP2041304B1 (en) 2006-06-12 2011-09-07 Hadasit Medical Research Services & Development Limited Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
KR20160072276A (ko) * 2006-11-09 2016-06-22 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
US8088786B2 (en) 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
HUP0600868A3 (en) * 2006-11-24 2009-03-30 Richter Gedeon Nyrt 5-{2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one hydrogen bromide polimorphs and process for their preparation
MX2009011681A (es) * 2007-05-18 2009-11-10 Scidose Llc Formulaciones de ziprasidona.
EP2197446A4 (en) * 2007-08-31 2012-01-25 Reddys Lab Ltd Dr PREPARATION OF HYDROCHLORIDE OF ZIPRASIDONE MONOHYDRATE
WO2009116085A2 (en) * 2008-03-11 2009-09-24 Alkem Laboratories Ltd. An improved process for the preparation of ziprasidone
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
NZ590682A (en) 2008-06-23 2012-09-28 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
WO2010073255A1 (en) * 2008-12-23 2010-07-01 Cadila Healthcare Limited Process for preparing ziprasidone
US8252801B1 (en) 2009-06-03 2012-08-28 Abbott Laboratories Treatment of schizophrenia and related disorders
ES2647361T3 (es) 2010-01-07 2017-12-21 Alkermes Pharma Ireland Limited Profármacos de sales de amonio cuaternario
BR112012016783A2 (pt) * 2010-01-11 2015-09-01 Orexigen Therapeutics Inc "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
CN102234272A (zh) * 2010-04-21 2011-11-09 上海医药工业研究院 盐酸齐拉西酮半水合物的制备方法
US20130108701A1 (en) 2010-05-25 2013-05-02 Krishna Murthy Bhavanasi Solid Dosage Forms of Antipsychotics
PL391810A1 (pl) 2010-07-14 2012-01-16 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Nowe sole ziprasidonu oraz sposoby ich otrzymywania
WO2012020424A1 (en) 2010-08-12 2012-02-16 Arch Pharmalabs Limited A short process for the preparation of ziprasidone and intermediates thereof
JP5684388B2 (ja) 2010-08-23 2015-03-11 アルカーメス ファーマ アイルランド リミテッド 抗精神病薬誘発性体重増加を治療するための方法
JP5916746B2 (ja) 2010-11-15 2016-05-11 エージンバイオ， インコーポレイテッド 認知障害を処置するためのピリダジン誘導体、組成物、および方法
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
LT3730132T (lt) 2012-06-06 2022-08-25 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN106068256B (zh) 2013-12-20 2020-10-23 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法
JP6987384B2 (ja) 2015-06-19 2021-12-22 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
US20170323239A1 (en) 2016-05-06 2017-11-09 General Electric Company Constrained time computing control system to simulate and optimize aircraft operations with dynamic thermodynamic state and asset utilization attainment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP7514534B2 (ja) 2018-06-19 2024-07-11 エージンバイオ， インコーポレイテッド 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
JPH0686253B2 (ja) * 1992-01-28 1994-11-02 株式会社日立東サービスエンジニアリング フレキシブルコンテナ収納体
IT1255263B (it) * 1992-04-02 1995-10-25 Metodo e composizione liquida per la realizzazione di scritte indelebili su un substrato cartaceo
DE69322707T2 (de) * 1992-07-31 1999-08-19 Bristol-Myers Squibb Company Diphenyl Oxazole-, Thiazole- und Imidazole-Derivate als Inhibitoren der Wiederaufnahme des Adenosins

Also Published As

Publication number Publication date
FI933804A0 (fi) 1993-08-31
DE9312903U1 (de) 1994-01-05
US5312925A (en) 1994-05-17
IL106777A0 (en) 1993-12-08
FI933804A (fi) 1994-03-02
RU2081116C1 (ru) 1997-06-10
CN1033641C (zh) 1996-12-25
NO300270B1 (no) 1997-05-05
JPH06157521A (ja) 1994-06-03
CA2105114A1 (en) 1994-03-02
PL173967B1 (pl) 1998-05-29
IL106777A (en) 1997-04-15
NO933093L (no) 1994-03-02
NO933093D0 (no) 1993-08-31
AU4600493A (en) 1994-06-16
KR940007025A (ko) 1994-04-26
PL300235A1 (en) 1994-04-05
CZ178993A3 (en) 1994-04-13
KR100632870B1 (ko) 2006-10-16
ZA936394B (en) 1995-02-28
NZ248543A (en) 1995-07-26
HU221725B1 (hu) 2002-12-28
CA2105114C (en) 2000-02-15
JP2742372B2 (ja) 1998-04-22
TW422845B (en) 2001-02-21
BR9303014A (pt) 1994-03-15
CZ285984B6 (cs) 1999-12-15
KR100278321B1 (ko) 2001-01-15
MX9305277A (es) 1994-03-31
EP0586191A1 (en) 1994-03-09
CN1089607A (zh) 1994-07-20
HU9302460D0 (en) 1993-11-29
PL174396B1 (pl) 1998-07-31
AU657231B2 (en) 1995-03-02
HUT67023A (en) 1995-01-30
EG20251A (en) 1998-05-31

Similar Documents

Publication Publication Date Title
FI115460B (fi) Menetelmä terapeuttisesti käyttökelpoisen 5-(2-(4-(1,2-bentsisotiatsol-3-yyli)-1-piperatsinyyli)etyyli)-6-kloori-1,3-dihydro-2H-indol-2-onihydrokloridin monohydraatin valmistamiseksi
KR0123441B1 (ko) 아릴 피페라지닐-헤테로사이클릭 화합물의 제조방법
US5338846A (en) Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
JPH0517457A (ja) ベンズイソチアゾールおよびベンズイソキサゾールピペラジン誘導体
HUT76638A (en) Acyl derivatives of azolones, pharmaceutical compositions containing them, process for producing them and their use as an anti-helicobacter agent
KR870001027B1 (ko) 카르복시이미드 유도체의 제조방법
RU2468015C2 (ru) Полиморфные формы деферасирокса (icl670a)
EP0683167A1 (en) Terazosin monohydrochloride and processes and intermediate for its production
FI84604C (fi) Foerfarande foer framstaellning av antipsykotiskt 8-/4-/4-(1-oxo-1,2-bensisotiazol-3-yl)-1-piperazinyl/butyl/ -8-azaspiro/4,5/dekan-7,9-dion eller salt daerav.
US3998953A (en) 1,3,7-Trisubstitued xanthine peripheral vasodilators
JPS59216877A (ja) 置換フエニル−２−（１ｈ）−ピリミジノン
EP0198235B1 (en) Imidazole derivatives having antimycotic and antibacterial activities, a process for the preparation thereof and pharmaceutical compositions containing them
DK2350082T3 (en) Choline and thromethamine salt of licofelone
GB2062637A (en) Imidazolylethoxy derivatives of quinoline-2-or 4-methanols
US20100113556A1 (en) Novel crystal forms of pyrrolylheptanoic acid derivatives
US4117131A (en) Method of inhibiting gastric acid secretions with 2-(4-pyrimidinyl)thioacetamides
JPS63275572A (ja) １，５−ベンゾチアゼピン誘導体
KR910006987B1 (ko) 아미노에틸 이미다졸의 제조방법

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 115460

Country of ref document: FI

MA Patent expired